FDA Approval

Showing 197 articles
Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Business

Moonshot AI's Latest Model Claims Edge Over U.S. Rivals as China's Tech Giants Secure Critical Nvidia Chips

Alibaba-backed Moonshot AI has unveiled an upgraded flagship model, Kimi K2.5, asserting superiority in video generation and agentic capabilities against leading U.S. models. The development coincides with Beijing's approval for major tech firms, including Alibaba, to import advanced Nvidia H200 AI chips, signaling a dual-track strategy in the intensifying global AI race.